

MDS Data Quality Initiative

In total 16 centres from 9 countries participated with the MDS DQI, contributing around 1500 patients.




	Before DQI (% complete)	After DQI (% complete)
PB blasts		
- At diagnosis	24%	57%
- At transplant	28%	77%
BM blasts		
- At diagnosis	28%	72%
- At transplant	29%	88%
Pre-treatments	51%	68%
Comorbidities	35%	97%
Cytogenetics	33%	88%
HLA report	36%	76%
Conditioning drugs	91%	100%
Prophylaxis drugs	90%	99%
Acute GvHD	64%	95%
Chronic GvHD	73%	98%
Follow Up (median, alive patients)	36 months	70 months

CMML Data Quality Initiative


	Before DQI (% complete)	After DQI (% complete)
Subclassification - At diagnosis	26%	53%
- At transplant	67%	79%
PB blasts - At diagnosis	26%	43%
- At transplant	30%	53%
BM blasts - At diagnosis	31%	51%
- At transplant	33%	63%
Pre-treatments	50%	64%
Comorbidities	41%	91%
Cytogenetics	44%	79%
HLA report	49%	70%
Conditioning drugs	87%	96%
Prophylaxis drugs	84%	93%
Acute GvHD	73%	90%
Chronic GvHD	75%	93%
Follow Up (median, alive patients)	16 months	32 months

In total 47 centres from 16 countries participated with the CMML DQI, contributing around 460 patients.



MPN Data Quality Initiative

In total 10 centres from 7 countries participated with the MPN DQI, contributing around 450 patients.



	Before DQI (% complete)	After DQI (% complete)
PB blasts		
- At diagnosis	29%	55%
- At transplant	34%	87%
BM blasts		
- At diagnosis	15%	25%
- At transplant	13%	30%
Pre-treatments	54%	93%
Comorbidities	56%	96%
Cytogenetics	27%	69%
Molecular Markers	51%	84%
HLA report	54%	88%
Conditioning drugs	96%	100%
Prophylaxis drugs	92%	99%
Acute GvHD	71%	94%
Chronic GvHD	78%	99%
Follow Up (median, alive patients)	35 months	62 months

Thank you for your efforts!